TearLab Corporation

Dr. Michael A. Lemp is an acknowledged leader in the field of dry eye/ocular surface disease. Over the past three decades, Dr. Lemp has published 185 scientific articles and four books and served on national, international and government advisory boards. He organized and chaired the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eye; this report stands as the worldwide standard for the definition, classification and design of clinical trials for dry eye. His seminal work in the understanding of tear film instability in dry eye states has advanced the knowledge of pathological events in the disease process. After obtaining an MD degree and completing residency training from Georgetown, he served as a Fellow in Corneal Disease at the Massachusetts Eye and Ear Infirmary.

In addition, Dr. Lemp worked at Schepens Eye Research Institute (Harvard Medical School) where he authored the initial papers on qualitative disorders of the tear film. He also served as Professor and Chairman of the Department of Ophthalmology at Georgetown University, as an officer and board member of many national and international ophthalmic organizations, member of the FDA Ophthalmic Devices Advisory Board, and NIH Study Sections and advisory committees. He is currently Clinical Professor of Ophthalmology at Georgetown and George Washington universities, Editor-in-Chief of The Ocular Surface – the international journal of review for ocular surface disease – and serves as a scientific advisor to many major ophthalmic pharmaceutical companies. Also, he is a scientific reviewer for all of the ophthalmic journals. Dr. Lemp has been a visiting professor at 68 universities and in 1998 received the Castroviejo Medal, the highest international prize for professional accomplishment in the field of corneal disease.

Benjamin Sullivan is a co–founder of the Company. Prior to obtaining his Ph.D. in Bioengineering at the University of California, San Diego, Benjamin spent six years researching effects of DED on molecular profiles of the tear film while at the Schepens Eye Research Institute, an affiliate of Harvard Medical School. Prior to that, he graduated from Boston University in 1997 with a B.S. (summa cum laude) in Biomedical Engineering. Benjamin has explored various aspects of the role of androgens within dry eye and has published several articles pertaining to the characterization of lipid distributions within dry eye patients. His current work is focused on applied electromechanical phenomena at the nanoscale with an emphasis on improving specificity of diagnostic assays.

Mr. Dumencu served as Occulogix's Chief Financial Officer and Treasurer between September 2003 and June 2005 and has been serving again in that capacity since the middle of April 2006.  Prior to his re-appointment as OccuLogix's Chief Financial Officer and Treasurer in April 2006, Mr.Dumencu had been serving as OccuLogix's Vice President, Finance.  From January 2003 to August 2003, Mr. Dumencu was a consultant for OccuLogix and TLC Vision, and from 1998 until 2002, Mr. Dumencu served in a variety of financial leadership positions at TLC Vision, including Controller.  Mr. Dumencu was employed in various financial management positions by Hawker Siddeley Canada, Inc., a manufacturing conglomerate, from 1978 to 1998.  Mr. Dumencu is a Chartered Accountant and a member of the Canadian Institute of Chartered Accountants.  He holds a Bachelor of Math degree from the University of Waterloo.

Mr. Walder, PA-C, 57, has over 30 years of experience of healthcare and management experience, both as a care giver and senior manager. Mr. Walder joined TearLab Corporation as Vice President of Operations in 2008. He is also a principal in The Samaritan Group, a consulting group specializing in medical services. Previously, he was the Vice President of Clinical Operations with Digirad, Corp., a leading developer of solid state gamma camera's and the largest provider of in-office cardiology imaging services. Prior to Digirad, Mr. Walder was the Business Unit Manager for Abbott Laboratories. Abbott Labs is a global organization that develops, manufactures and distributes healthcare products and pharmaceuticals. Mr. Walder graduated from California State College with a Bachelors in Electrical Engineering, the University of Southern California with a Baccalaureate in Medicine and the University of Phoenix with degrees in Business Administration and Management.

Michael Berg has over 25 years experience introducing new technology into the professional healthcare marketplace, through his own companies and as consultant to the industry. He is experienced in product development and acquisition, finance, manufacturing, marketing and strategic planning, domestic and international distribution, reimbursement and regulatory affairs. Michael, having studied and lived in Japan is an expert in Japanese regulatory and distribution strategies. As 50% joint–venture owner and President of HemoCue, Inc, Michael launched a blood hemoglobin point–of–care analyzer in the U.S. through a unique distribution model he created, the Independent Direct Distribution Organization. This model incorporated an educational approach to convert the healthcare profession from the prevailing spun microhematocrit technology, to a more expensive but accurate and safer hemoglobin test for the diagnosis of classic anemia. This distribution system provided all the advantages of a direct sales force at a fraction of the cost. Under this model, 13,000 HemoCue analyzers were sold into the market in the first 4 years of operation, with continued placement to date of 30,000+ instruments resulting in a business exceeding $50 million in annual revenue. Michael divested all interest in HemoCue, Inc. upon Mallinckrodt's acquisition of the parent company, HemoCue AB, in January 1991 for $100 million.

As a consultant to the industry, Michael has repeatedly formulated and implemented successful strategies to obtain CLIA Waiver categorization for point–of–care technology, solicited and obtained CPT coding through the American Medical Association process, and facilitated strong reimbursement for his clients through the Medicare (CMS) system. Focused on market development and physician education, Michael is experienced in the design and coordination of clinical studies, positioning products to meet clinical guidelines, evidence–based medicine and pay–for–performance criteria, and co–promotion with the pharmaceutical industry to link diagnosis and therapy. Michael received his BA from the University of Notre Dame and currently resides in Orange County California.

Steve Zmina is our Vice President of Manufacturing & Engineering. Steve has more than 28 years of product development experience in a number of high technology industries, including medical, telecommunications, semiconductor, industrial and high volume consumer products. His wide range of skills include product development, product marketing, manufacturing, and operation.

Prior to TearLab Corporation, Steve was the Vice President of Product Development at Thermoscan, in San Diego, California, developing professional and consumer infrared ear thermometers. He has also been responsible for the development of a variety of high volume consumer products for Tandy Electronics. While at Tandy, his product development team developed over 40 new, high volume consumer products. He introduced digital signal processing into very low cost consumer products to significantly improve product performance and value to the customer. Steve has also held a number of other executive level positions in the semiconductor and power supply industries, developing products for the consumer and industrial markets. Steve has BSEE and MSEE degrees from Purdue University in semiconductor electronics.

With US and global experience in both packaged goods and pharmaceutical products from the advertising agency and industry side, Tracy brings more than 17 years of marketing and product launch experience to the TearLab Corporation team.

Prior to joining Tearlab Corporation, Tracy was the Executive Director of Branding at Alimera Sciences, in Atlanta Georgia where she launched their first ethically promoted OTC product in record time. Tracy has created and managed brand strategies for numerous ophthalmic OTC and prescription products. In her role as Executive Director, US Marketing at Novartis Ophthalmics, Tracy managed a team of product managers overseeing the anterior segment business for the company.

Before moving to the pharmaceutical industry, Tracy worked for healthcare advertising agency, Adair-Greene where she managed the Novartis Ophthalmics account. International consumer experience was achieved during her tenure at McCann-Erickson in Moscow, Russia, a multi-national advertising agency. As head of New Business, Tracy brought a number of key accounts into the agency. In her role as Group Account Supervisor, she led a diverse brand team which managed clients such as Johnson & Johnson, Nestle and Gillette.

Throughout her career, Tracy has had proven success in building sustainable brand propositions which meet company P&L objectives.